https://www.asimov.com https://www.asimov.com/about https://www.asimov.com/contact https://www.asimov.com/lv-edge-system https://www.asimov.com/news https://www.asimov.com/approach https://www.asimov.com/privacy-policy https://www.asimov.com/terms-of-service https://www.asimov.com/cell-line-development-services https://www.asimov.com/kernel https://www.asimov.com/aav-edge-system https://www.asimov.com/cho-edge-expression-system https://www.asimov.com/rna-edge-system https://www.asimov.com/events https://www.asimov.com/events-asgct-2026 https://www.asimov.com/events-pegs-2026 https://www.asimov.com/news/a-programming-language-for-living-cells https://www.asimov.com/news/andreessen-horowitz https://www.asimov.com/news/andreessen-horowitz-backs-asimovs-synthetic-biology-cad-software https://www.asimov.com/news/andreessen-horowitz-leads-seed-round-in-mit-born-genetic-circuits-startup https://www.asimov.com/news/asimov-achieves-10x-improvement-in-lentiviral-production-launches-new-stable-cell-line-development-service https://www.asimov.com/news/asimov-and-agc-biologics-team-up-to-provide-a-cost-effective-simplified-and-secure-manufacturing-approach-for-viral-vector-production https://www.asimov.com/news/asimov-and-center-for-breakthrough-medicines-form-strategic-partnership-for-viral-vector-production https://www.asimov.com/news/asimov-and-revopsis-therapeutics-sign-licensing-agreement https://www.asimov.com/news/asimov-announces-cell-line-development-partnership-with-ottimo-pharma-to-accelerate-cancer-immunotherapys-path-to-clinic https://www.asimov.com/news/asimov-announces-cell-line-development-partnership-with-score-pharma-to-advance-biosuperior-antibody-therapeutics https://www.asimov.com/news/asimov-enters-into-agreement-with-bardas-biomap-consortium-to-advance-production-of-medical-countermeasures-against-ebola-and-deadly-viruses https://www.asimov.com/news/asimov-introduces-its-ai-driven-4th-generation-cho-edge-system-with-increased-titer-guarantee https://www.asimov.com/news/asimov-labs https://www.asimov.com/news/asimov-launches-aav-edge https://www.asimov.com/news/asimov-launches-cho-edge-rapid-pools-to-bridge-biologics-discovery-and-cmc-with-predictive-stable-expression https://www.asimov.com/news/asimov-launches-lv-edge-packaging-system-to-optimize-lentivirus-production https://www.asimov.com/news/asimov-launches-rna-edge-a-lab-in-the-loop-platform-for-ai-optimization-of-rna-therapeutic-candidates https://www.asimov.com/news/asimov-launches-stable-aav-producer-cell-lines-setting-a-new-standard-for-viral-vector-manufacturing https://www.asimov.com/news/asimov-partners-with-igem-to-support-the-next-generation-of-synthetic-biologists https://www.asimov.com/news/asimov-press https://www.asimov.com/news/asimov-raises-200-million-to-advance-therapeutics-design-and-manufacturing-with-synthetic-biology https://www.asimov.com/news/asimov-selected-by-darpa-to-develop-artificial-intelligence-design-engine-for-synthetic-biology https://www.asimov.com/news/asimov-to-present-data-on-ai-designed-tissue-specific-promoters-at-upcoming-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct https://www.asimov.com/news/bio-programming-toolkit-maker-asimov-launches-with-4-7m-from-andreessen-horowit https://www.asimov.com/news/biologists-would-love-to-program-cells-as-if-they-were-computer-chips https://www.asimov.com/news/cellular-circuit-computes-with-dna https://www.asimov.com/news/cho-edge-system-licensed-by-novo-nordisk https://www.asimov.com/news/drug-manufacture-has-one-huge-flaw-this-synthetic-biology-startup-just-raised-200m-to-fix-it https://www.asimov.com/news/genetic-circuits-startup-asimov-raises-seed-round-led-by-andreessen-horowitz https://www.asimov.com/news/how-cambridge-startup-asimov-is-doing-business-with-genetic-circuits https://www.asimov.com/news/how-programmable-dna-strands-could-control-healing https://www.asimov.com/news/lift-off https://www.asimov.com/news/lotte-biologics-and-asimov-announce-partnership https://www.asimov.com/news/mit-spinout-asimov-implements-programming-language-for-cells https://www.asimov.com/news/mit-startup-exchange-names-asimov-to-stex25 https://www.asimov.com/news/optimizing-bispecific-antibody-expression-with-amgen https://www.asimov.com/news/the-automatic-design-tools-that-are-changing-synthetic-biology https://www.asimov.com/blog-post/aav-foundations https://www.asimov.com/blog-post/ai-promoters https://www.asimov.com/blog-post/asimov-labs https://www.asimov.com/blog-post/asimov-press https://www.asimov.com/blog-post/beginners-guide-to-mammalian-genetic-design https://www.asimov.com/blog-post/central-dogma https://www.asimov.com/blog-post/cho https://www.asimov.com/blog-post/computer-aided-design-of-biology https://www.asimov.com/blog-post/engineered-cell-therapies https://www.asimov.com/blog-post/genetic-design https://www.asimov.com/blog-post/github https://www.asimov.com/blog-post/lift-off https://www.asimov.com/blog-post/making-lenti https://www.asimov.com/blog-post/metabolic-simulator https://www.asimov.com/blog-post/partnering-with-igem https://www.asimov.com/blog-post/the-circuitry-in-our-cells https://www.asimov.com/resources/aav-edge https://www.asimov.com/resources/advanced-process-development-to-tune-product-quality-cell-uk-2023 https://www.asimov.com/resources/bridging-discovery-and-cmc-with-asimovs-rapid-pools https://www.asimov.com/resources/engineered-cell-therapies https://www.asimov.com/resources/making-lenti https://www.asimov.com/resources/medicine-making-tools https://www.asimov.com/resources/metabolic-simulator https://www.asimov.com/resources/model-driven-synbio-approaches-to-engineer-improved-stable-cell-lines-for-lentivirus-manufacturing https://www.asimov.com/resources/next-gen-lentiviral-vector-manufacturing-improving-scalability-control-and-quality https://www.asimov.com/resources/quantitative-synthetic-biology-for-biologics-production-white-paper https://www.asimov.com/resources/reducing-cost-and-risk-in-lentiviral-manufacturing https://www.asimov.com/resources/the-future-of-biomanufacturing-ai-driven-cell-line-development-and-bioprocess-design https://www.asimov.com/faqs/do-you-optimize-codons-for-translation https://www.asimov.com/faqs/does-asimovs-approach-vary-between-mono--and-multi-specific-architectures https://www.asimov.com/faqs/how-do-you-balance-heavy-and-light-chains https://www.asimov.com/faqs/how-do-you-select-a-signal-peptide https://www.asimov.com/faqs/how-does-your-titer-guarantee-work https://www.asimov.com/faqs/how-many-copies-of-the-antibody-expressing-plasmid-end-up-in-the-cell-line-when-using-a-transposase https://www.asimov.com/faqs/how-stable-are-cell-lines-generated-using-cho-edge https://www.asimov.com/faqs/replication-competent-lentivirus-concerns https://www.asimov.com/faqs/why-would-glutamine-synthetase-expression-affect-antibody-expression